Cytokinetics (NASDAQ:CYTK – Free Report) had its price objective lowered by Truist Financial from $86.00 to $70.00 in a research report released on Wednesday morning, Benzinga reports. Truist Financial currently has a buy rating on the biopharmaceutical company’s stock. Several other research firms have also recently weighed in on CYTK. JMP Securities cut their price […]
Cytokinetics (NASDAQ:CYTK – Free Report) had its price target decreased by JMP Securities from $106.00 to $78.00 in a research note issued to investors on Tuesday, Benzinga reports. JMP Securities currently has a market outperform rating on the biopharmaceutical company’s stock. CYTK has been the subject of a number of other reports. Mizuho dropped their […]
Barclays (NYSE:BCS) Shares Gap Up to $10 98 theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Cytokinetics (NASDAQ:CYTK – Get Free Report) had its target price decreased by equities research analysts at Truist Financial from $86.00 to $70.00 in a research note issued on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Truist Financial’s price target would indicate a potential upside of 45.20% from […]
Paradigm Asset Management Co. LLC purchased a new position in shares of STMicroelectronics (NYSE:STM – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 19,600 shares of the semiconductor producer’s stock, valued at approximately $980,000. Other hedge […]